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Abstract
Background: Earlier diagnosis followed by multi-factorial cardiovascular risk intervention may improve outcomes in
Type 2 Diabetes Mellitus (T2DM). Latent phase identification through screening requires structured, appropriately
targeted population-based approaches. Providers responsible for implementing screening policy await evidence of
clinical and cost effectiveness from randomised intervention trials in screen-detected T2DM cases. UK South Asians
are at particularly high risk of abnormal glucose tolerance and T2DM. To be effective national screening
programmes must achieve good coverage across the population by identifying barriers to the detection of disease
and adapting to the delivery of earlier care. Here we describe the rationale and methods of a systematic
community screening programme and randomised controlled trial of cardiovascular risk management within a UK
multiethnic setting (ADDITION-Leicester).
Design: A single-blind cluster randomised, parallel group trial among people with screen-detected T2DM
comparing a protocol driven intensive multi-factorial treatment with conventional care.
Methods: ADDITION-Leicester consists of community-based screening and intervention phases within 20 general
practices coordinated from a single academic research centre. Screening adopts a universal diagnostic approach via
repeated 75g-Oral Glucose Tolerance Tests within an eligible non-diabetic population of 66,320 individuals aged 40-75
years (25-75 years South Asian). Volunteers also provide detailed medical and family histories; complete health
questionnaires, undergo anthropometric measures, lipid profiling and a proteinuria assessment. Primary outcome is
reduction in modelled Coronary Heart Disease (UKPDS CHD) risk at five years. Seven thousand (30% of South Asian ethnic
origin) volunteers over three years will be recruited to identify a screen-detected T2DM cohort (n = 285) powered to
detected a 6% relative difference (80% power, alpha 0.05) between treatment groups at one year. Randomisation will
occur at practice-level with newly diagnosed T2DM cases receiving either conventional (according to current national
guidelines) or intensive (algorithmic target-driven multi-factorial cardiovascular risk intervention) treatments.
Discussion: ADDITION-Leicester is the largest multiethnic (targeting >30% South Asian recruitment) community T2DM and
vascular risk screening programme in the UK. By assessing feasibility and efficacy of T2DM screening, it will inform national
disease prevention policy and contribute significantly to our understanding of the health care needs of UK South Asians.
Trial registration: Clinicaltrial.gov (NCT00318032).
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Introduction
Type 2 Diabetes Mellitus (T2DM) is an increasingly
common, potentially devastating disease characterised
by prolonged asymptomatic hyperglycaemia and insi-
dious vascular complications [1]. At present, 50% of new
T2DM cases have demonstrable atherosclerosis at diag-
nosis and glucose abnormalities commonly characterise
acute coronary and cerebro-vascular thrombotic events
in people not known to have the disease [2,3]. Recent
outcome studies suggest intensive glucose control
among people with long-standing T2DM is associated
with limited reduction in cardiovascular events, whereas
sustained optimisation earlier in the trajectory of the
disease may be associated with significant micro and
macro-vascular benefits [4-6].
Screening for T2DM
The frequency of T2DM, its latent presentation and
potentially preventable burden of complications make it
an attractive target for earlier identification and inter-
vention through screening [7,8]. Despite convincing
rationale there is in fact little evidence that this
approach improves T2DM outcomes, or that treatment
effective for conventionally diagnosed cases produces
greater benefit if commenced within the lead time
between detection by screening and clinical diagnosis
[9]. Furthermore the continuous relationship between
glucose concentration and cardiovascular disease well
below the diagnostic threshold for T2DM [10] suggests
screening programmes should include non-diabetes
range hyperglycaemia (Impaired Fasting Glycaemia and
Impaired Glucose Tolerance) if they are to improve
population level outcomes. Primary prevention studies
in these groups result in weight loss and slow progres-
sion to diabetes [11,12] supporting the concept of earlier
identification and lifestyle intervention for those at risk
of T2DM.
It is currently unclear how effective population screen-
ing will be at identifying people with T2DM or whether
incorporating a mix of cardio-metabolic factors, including
non-diabetes range hyperglycaemia, into screening pro-
grammes will substantially increase the yield of individuals
at high cardiovascular risk [9]. There are additional con-
cerns with respect to the potential adverse consequences
of screening [13,14], its cost-effectiveness [15] and the
magnitude of achievable cardiovascular risk reduction
within this largely symptom-free population [16].
Black and Minority Ethnic (BME) groups
Certain ethnic groups in the UK are at particularly high
risk of abnormal glucose tolerance and T2DM, with
reported prevalence 2-6 times that of the background
white European population [17,18]. Speculated higher
than average T2DM progression rates amongst UK
south Asians are supported by significant global varia-
tion in reported incident cases but robust prospective
data is lacking within Westernised ethnic minority
populations. Studies gauging reaction to T2DM screen-
ing within these groups is also limited [19] but suggests
response rates are more likely to be influenced by cul-
tural beliefs, social stigma attached to certain conditions,
and the attitude of the local community to western
health care methods [20,21]. It is essential barriers to
screening activity together with the effort required to
overcome them are quantified if they are to inform
effective planning and implementation of culturally
sensitive interventions [22].
The ADDITION study
As a result of such critical uncertainties the UK
National Screening Committee currently recommend a
targeted rather than universal approach, with screening
confined to groups at particularly high risk of T2DM
[23,24]. There is some evidence that UK general physi-
cians are increasingly carrying out opportunistic or
planned community screening of their patients [25,26].
Implementation of the National Health Service (NHS)
vascular check programme recommending glucose test-
ing for 40-70 year olds will undoubtedly further increase
T2DM screening activity in the UK [27].
Priority should be directed towards developing a
robust evidence base informing national policy and pro-
tecting against indiscriminate, poorly coordinated
screening programmes. The results of randomised con-
trolled trials among screen-detected cases with out-
comes assessing vascular complications, health
satisfaction, process of care indicators and cost are vital
to this process.
ADDITION (Anglo-Danish-Dutch Study of Intensive
Treatment in People with Screen Detected Diabetes in
Primary Care) is a multi-centred randomised controlled
trial evaluating the effectiveness of multi-factorial treat-
ment on risk of cardiovascular disease events among
over 2500 patients with screen-detected diabetes
[28-30]. ADDITION-Leicester contributes to this multi-
centre study but is also a stand-alone trial evaluating
screening within a UK multiethnic group and quantify-
ing the efficacy of optimised treatments on modelled
cardiovascular risk over five years.
This paper describes the aims and methods of both
screening and intervention phases of the ADDITION-
Leicester study.
ADDITION-Leicester Objectives
The primary aim of the ADDITION-Leicester study is to
evaluate the efficacy and cost-effectiveness of 1) a universal
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screening programme for T2DM and 2) intensive multi-
factorial cardio-protection in those identified with T2DM
within a UK multiethnic population. This objective will be
achieved by determining the feasibility of screening as
defined by the uptake and yield achievable within a primary
care setting with a known 20-30% ethnic minority (Indo-
Asian) presence. The health service and patient costs of
screening for T2DM and other glucose abnormalities will
be evaluated, together with objective assessments of five-
year cardiovascular risk and mortality. ADDITION-Leice-
ster is registered with ClinicalTrials.gov with identifier
NCT00318032.
The study consists of two phases a screening phase,
employing a universal gold standard diagnostic test for
T2DM and an intervention phase, delivering a rando-
mised trial of structured cardiovascular risk intervention
in screen-detected cases.
A third element, the ADDITION-Leicester pre-dia-
betes cohort study prospectively assesses non-diabetes
range fasting and post-challenge hyperglycaemia. The
aim of the ADDITION-Leicester Prediabetes Cohort
Study is to determine the annual rate of progression
over five years of follow up and to characterise T2DM
susceptibility phenotypes.
Methods/Design
ADDITION-Leicester adopts a community based non-
selective screening approach within a representative
cluster of General Practices. The study is coordinated
from a regional academic centre hosted by the Univer-
sity of Leicester and University Hospitals of Leicester,
NHS Trust but delivered in primary care through an
established diabetes research network (South East Mid-
lands Diabetes Research Network). The study is sup-
ported by competitive Department of Health project and
NHS Support for Science grants. Ethical approval was
obtained from the University Hospitals of Leicester
(UHL09320) and Leicestershire Primary Care Research
Alliance (64/2004) local research ethics committees. The
study was conducted in accordance with the principles
of the 1996 Helsinki Declaration. Written informed con-
sent was obtained for all participants involved in both
phases of ADDITION-Leicester study at the time of dia-
betes screening.
Study location
Volunteers were recruited from general practices in
urban, suburban and rural Leicestershire, England, Uni-
ted Kingdom. Screening focuses upon Leicester, the
county capital with an estimated population of 279,921,
an ethnic minority prevalence of 32% (82% Gujarati
speaking first or second generation Indo-Asians) and a
local authority ranked amongst the twenty most
deprived in the United Kingdom (2006 census data
available at http://www.leicester.gov.uk).
Phase 1: The screening phase
Identification of an eligible population: practice data
handling and electronic mailers
Clinical leads from the 46 General Practices forming the
Leicestershire and Rutland Strategic Health Authority
were approached to participate in ADDITION-Leicester.
Personalised letters were sent to the practice manager,
partners and nursing staff of each practice reiterating
the importance of the study to primary care, the roles of
individual practices, the required commitment and the
availability of remuneration for all incurred costs. A
principal investigator and member of the research team
visited interested practices to discuss the study in detail.
28 practices responded positively with consent for an
initial database search using an extraction programme
compatible with the widely used clinical EMIS (Egton
Medical Information Systems Ltd, York UK) system.
This specialised software generates an anonymised Mas-
ter Practice List (MPL) that matches individual data to a
random unique identifier (a six-digit and single letter
ADDITION-Leicester number). An MPL representative
of the practice population is considered essential for
further participation in the study and eight practices
were excluded at this stage due to data extraction failure
or search software incompatibility. Practices were con-
sidered eligible if the MPL captures more than 70% of
the total practice population. The MPL captures practice
population demographics (age, sex, occupation, medical
history, active prescriptions) and known T2DM fre-
quency, enabling future comparison of responder/non-
responder characteristics and total T2DM disease preva-
lence. Applying the study criteria to the MPL produces
an eligible population list which is reunited with the
practice dataset to provide personal details necessary to
post an invitation for screening (first mailer). Those
meeting the inclusion criteria are sent details of the
study along with a returnable request for culturally
appropriate information written in five major South
Asian languages (Hindi, Gujarati, Bengali, Urdu and
Punjabi). Having expressed an interest in the study,
potential participants are sent individual screening
appointments at either a hospital site or a mobile
screening unit located within their community. Non-
responders are sent a second invitation (second mailer)
within six months. To ensure confidentiality is main-
tained practice staff handle initial database searches and
mailing tasks. South Asian ethnicity is defined at this
stage by forename and surname mapping using specia-
lised software developed from census data (Nam Peh-
chan) [31]. Mean practice deprivation scores are
calculated from individual MPL data using an Index of
Medical Deprivation (IMD 2007) [32]
The size, geographical location and deprivation status
of the 20 practices participating in ADDITION-Leicester
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is shown in Figure 1. Our calculated mean practice IMD
scores match national survey deprivation quintiles and
depicted practices within the Leicester city boundary
appear typical of an urban UK deprivation distribution.
To ensure all 20 sites are covered within the study time-
frame, in six practices the entire eligible population have
been sent information regarding the study whilst a ran-
dom sample of the population are included in the
remaining practices.
Inclusion and exclusion criteria for the study are simi-
lar to the multi-centre ADDITION-Europe study [28].
Inclusion criteria are white Europeans between the ages
of 40-75 years and south Asians, Afro-Caribbean’s and
other races between the ages of 25-75 years. A lower
age cut-off for BME groups was chosen due to the
reported higher risk of T2DM. People with the following
pre-existing conditions are excluded (general practice
diagnosis and database recorded), T2DM, terminal ill-
nesses with a likely prognosis of less than 12 months,
psychiatric illness likely to hinder informed consent,
pregnancy and lactation.
Screening visit measurements
Standardised procedures are in place across screening
sites to ensure universal gold-standard diagnostic testing
for T2DM, IFG and IGT [33]. Individuals are asked to
fast for eight hours prior to attending a screening
appointment and to bring a list of prescribed medica-
tions with them. Before beginning the over night fast
participants are asked to consume their regular evening
meal and snacks, but refrain from alcohol consumption.
At baseline (V0) and annual pre diabetes cohort screen-
ing visits a standard 75g oral glucose tolerance test
(OGTT) is undertaken following informed consent. This
test is postponed if in the preceding three days instruc-
tions to follow a normal unrestricted diet are not fol-
lowed or participants report fever or unusual physical
activity. On the day of testing prescribed morning medi-
cations are permitted but participants are asked not to
run to their appointment or smoke until after the test.
Plasma samples are obtained immediately before (fasting
plasma glucose FPG) and 120 minutes after the glucose
challenge (two hours post challenge glucose 120-PG)
along with fasting samples for serum urea and electro-
lytes (UE), liver function tests (LFT), lipids (total choles-
terol, LDL-cholesterol, HDL-cholesterol, triglycerides),
HbA1c% (glycosylated haemoglobin) and renal function
(creatinine and modification of diet in renal disease esti-
mated glomerular filtration rate (MDRD eGFR))
(table 1). A spot urine sample for urinalysis and albumin
excretion rate is also collected.
Anthropometric measurements are performed by
trained staff following standard operating procedures,
Figure 1 Leicester City wards by quintiles deprivation (IMD2007).
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with height being measured to the nearest 0.1 cm using
a rigid stadiometer and weight in light indoor clothing
measured to the nearest 0.1 kg with a Tanita scale
(Tanita, Europe). Body fat percentage is measured via
calibrated bio impedance (Tanita, Europe). Body mass
index (kgm-2) is defined as weight in kilograms divided
by height in metres squared. Waist circumference was
measured at the mid-point between the lower costal
margin and the level of the anterior superior iliac crest
to the nearest 0.1 cm.
Brachial blood pressure is measured three times using
standardised Omron M7 digital sphygmomanometers
(Omron Healthcare, Milton Keynes, UK) with the parti-
cipant in a seated position. An average of the second
Table 1 Summary of assessments performed at Baseline (V0), annual pre diabetes and randomised controlled trial
(RCT) visits (V1-5) of the ADDITION-Leicester study
Visit Baseline
Screening
(v0)
Pre diabetes
annual
cohort
T2DM RCT
Year 1 (v1)
intensive/
routine
T2DM RCT
Year 2 (v2)
Intensive
T2DM RCT
Year 3 (v3)
Intensive*
/routine
T2DM RCT
Year 4(v4)
intensive
only
T2DM RCT
Year 5 (v5)
intensive/
routine
Medical Procedures:
Blood Pressure √ √ √ √ √ √ √
Electrocardiogram (ECG) √ √ √ √ √* √ √
Foot Check - - √ √ √* √ √
Biochemical measurements:
75g-OGTT: Fasting & 120 min glucose √ √ - - - - -
UE, LFT, Lipid profile, HbA1c% √ √ √ √ √ √ √
Renal function & urine ACR √ √ √ √ √ √ √
TFT - - √ √ √* √ √
Anthropometric measurements:
Height √ √ √ √ √ √ √
Weight √ √ √ √ √ √ √
Hip/Waist circumference √ √ √ √ √* √ √
Bioimpedence (% body fat) √ √ √ √ √* √ √
Body Mass Index (BMI) √ √ √ √ √ √ √
Screening Questionnaires*:
Medical/family history/medications √ √ √ √ √* √ √
Alcohol/smoking status √ √ √ √ √* √ √
Self-reported Questionnaires:
Findrisc[45], Cambridge risk scores[46] √ √ √ √ √* √ √
EuroQol, EQ-5D[47] √ √ √ √ √* √ √
WHO-5, BFI 44[48] √ √ √ √ √* √ √
IPAQ[49], Berlin ESS[50] √ √ √ √ √* √ √
Michigan neuropathy[51] √ √ √ √ √* √ √
T2DM: Life Quality/treatment satisfaction - - √ √ √ √ √
ADDQoL[52], DTSQ[52], W-BQ 28[52]
Arterial measurements sub study:
cfPWV, PCA[36,37] √ √ √ - - - √
Biobank storage aliquots:
8 × 2 ml Plasma(4), serum (4), √ √ √ √ √* √ √
Genetic Sample:
Whole blood (EDTA) √ - - - - - -
Key:
OGTT: 75 g Oral Glucose Tolerance Test (preparation as per WHO expert consensus report -1999)
UE: Biochemistry Urea & Electrolytes panel ACR: Albumin:Creatinine Ratio
LFT: Liver Function Tests (Bilirubin, alanine transaminase, alkaline phosphatase, gamma glutamyl transpeptidase)
HbA1c%: Glycosylated Haemoglobin
Lipid profile: Total, LDL, HDL Cholesterol & Triglycerides
TFT: Thyroid Function Test (Thyroid Stimulating Hormone, free thyroxine T4)
cfPWV, PCA: carotid-femoral Pulse wave Velocity Pulse Contour Analysis (Photoplethysmography derived)
Screening Questionnaires*: Completed during Interview with trained research nurse
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and third readings is recorded as per British Hyperten-
sion Society guidelines [34] with written instructions for
abnormal readings. A 12 Lead electrocardiogram (ECG)
is performed using a Nihon Kohden CardioFax Gem
machine (Nihon Kohden Europe GmbH, Rosbach vor
der Höhe, Germany). An in-house physician interprets
ECGs on the day of the visit, codes for ischaemia and
left ventricular hypertrophy [35] and reports back to the
general practitioner.
Self-completed questionnaires are used to assess base-
line smoking status, alcohol consumption, occupation,
and ethnicity. Validated questionnaires measuring physi-
cal activity, sleep quality, risk of diabetes, neuropathy,
and diabetes-specific psychological domains of well
being and anxiety are also included (table 1). All mea-
surements are performed by a dedicated team of
research nurses trained to document relevant medical
information and family history on a standardised case
report form during a 20 minute one to one interview on
the day of screening. The clinical team are unaware of
participants study group allocation or glucose diagnosis.
At major visits (V0-V4, and pre diabetes assessments)
further venepuncture is performed for future biomarker
research (table 1). Consent is obtained for the -80°C sto-
rage of multiple anonymised serum, plasma and whole
blood aliquots. These samples contribute to a biobank
facilitating translational research exploring the patho-
genesis of insulin resistance, vascular complications and
genetics of T2DM.
An option for further physiological measurements is
incorporated as a sub study amendment at visits V0, V1
and V4. Volunteers consent to return on a separate
occasion for non-invasive arterial assessments and blood
tests. Trans-cutaneous ultrasonic Pulse Wave Velocity
(cfPWV), and digital photoplethysmographic pulse con-
tour analysis (PCA) are performed under controlled
conditions using commercially available equipment
(PT4000, Cardinal Healthcare, Basingstoke, UK) [36,37].
Diagnosis and reporting
Results are relayed via written correspondence and cop-
ied to participant and general practitioner. All biochem-
ical measurements are performed in house at the
University Hospitals of Leicester NHS trust. Glucose
samples are taken in fluoride oxalate test tubes and
placed immediately in a portable 4 litre 4°C refrigerator
(also available on board the mobile screening unit).
HbA1c% is analysed by a DCCT aligned Biorad Variant
HPLC II system (Bio-Rad laboratories, Hemel Hemp-
stead, UK). The imprecision coefficient of variation of
this machinery is <0.1%, the reference intervals fit with
national recommendations valid for carriers of variant
Hb S, C and Q. Samples are processed within a maxi-
mum of two hours, using an Abbott Aeroset clinical
chemistry analyser (Abbott laboratories, Maidenhead,
UK), which employs the hexokinase enzymatic method.
This machinery has an imprecision coefficient of varia-
tion of 1.61%. Serum total cholesterol, HDL-cholesterol,
LDL-cholesterol and triglycerides are measured by
means of enzymatic techniques (Dade Behring Dimen-
sion analyser, Newark, USA). Plasma creatinine is ana-
lysed with kinetic colorimetric methods. Plasma levels of
urea and electrolytes, bilirubin, alanine aminotransferase,
alkaline phosphatase and thyroid stimulating hormone
are analysed by means of the Dade Behring Dimension
analyser.
Participants are categorised according to World
Health Organisation (WHO) criteria [33]. Diabetes is
defined as a fasting blood glucose of greater or equal to
7 mmoll-1 and/or 120-PG of greater than or equal to
11.1 mmoll-1. Impaired Fasting Glycaemia (IFG) is
defined as a fasting blood glucose concentration of
between 6.1 and 6.9 mmoll-1 inclusive and IGT as a
blood glucose concentration of between 7.8 and 11
mmoll-1 inclusive. Impaired Glucose Regulation (IGR) is
defined as any combination of IFG and/or IGT. The
diagnosis of T2DM is confirmed by an in house physi-
cian on the basis of two abnormal glucose results
obtained on separate visits, unless hyperosmolar symp-
toms suggestive of hyperglycaemia are reported at the
screening visit. Asymptomatic individuals with a dia-
betes range OGTT are asked to maintain their current
lifestyle and return for a confirmatory test (re screen)
within one week. For a diagnosis of T2DM in asympto-
matic individuals, one positive result from either a fast-
ing and/or 120-PG is required on both visits. In the
event of discordant OGTT results (eg. baseline diabetes
followed by rescreen IGR) participants are categorised
as having IGR (figure 2). Volunteers diagnosed with dia-
betes are entered into a cluster randomised controlled
trial of multi-factorial cardiovascular risk intervention
whilst those identified with IGR are given lifestyle advice
and invited to join the ADDITION-Leicester prediabetes
cohort study.
ADDITION-Leicester Pre diabetes cohort study
Non-diabetes range asymptomatic hyperglycaemia is of
clinical relevance to screening programmes due to the
associated increased risk of T2DM and cardiovascular
disease. Volunteers found to be within fasting or post-
challenge glucose categories of IFG and IGT (collective
lay-term prediabetes) at baseline are provided with writ-
ten lifestyle advice and invited for annual screening. The
ADDITION-Leicester prediabetes cohort study annual
screening protocol is identical to the baseline visit
(table 1), all results are relayed to participant and gen-
eral practitioner and those with diabetes range results
are recalled for a second glucose tolerance test. The
process for continued follow up differs however, as
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newly diagnosed T2DM is considered an endpoint and
the case is returned to the care of the primary care spe-
cialist rather than entering the trial phase. Continued
Prediabetes or normal glucose tolerance range results
are invited for further annual assessments.
Phase 2: A randomised controlled trial of multifactorial
intervention in individuals with screen-detected T2DM
Phase 2 is a pragmatic, cluster randomised, parallel
group trial among people with screen-detected T2DM
comparing intensive multi-factorial treatment with rou-
tine care in general practice according to national
guidelines.
Randomisation is performed by an independent com-
mittee provided with practice demographics, deprivation
status and approximate T2DM prevalence of individual
practices. Practices and not individuals are randomised
via a minimisation procedure with a 1:1 ratio. The
screen detected T2DM control group (routine care arm)
receive “usual care” within the primary care setting,
according to national recommendations for management
of T2DM and cardiovascular disease [38]. These partici-
pants will be reviewed one and five years post diagnosis,
when anthropometric and biochemical data will be col-
lected. The screen detected T2DM intervention group
(intensive care arm) are introduced to dedicated, specia-
list physicians and nurses who provide a structured,
intensified, protocol-driven, multi-factorial approach
again within the primary care setting (table 2).
Routine care arm intervention
Screen-detected T2DM cases entering the control group
(routine care arm) receive the standard of care normally
provided by their primary health care team. Within 24
hours of diagnosis a letter detailing the results of
screening is faxed to the practice, the participant is
informed (where possible via telephone contact) and an
urgent appointment with their general practitioner
advised.
At the time of randomisation each practice is sent a
copy of and electronic links to Leicestershire evidence
based guidelines adapted from national recommenda-
tions for diabetes care http://www.leicestershirediabetes.
org.uk/[38]. At the time of writing these included local
targets and protocol considered appropriate for effective
cardiovascular risk management in T2DM. Specific local
recommendations advise a glycosylated haemoglobin
(HbA1c%) of <7.0%, blood pressure of <140/85 mmHg
and a serum total cholesterol of <4.0 mmoll-1. Systema-
tic evidence-based standards of care are expected of all
UK general practices engaged in delivering diabetes ser-
vices as outlined in the NHS National Service Frame-
work for Diabetes [39]. All participating practices are
also performance managed by active participation in the
quality outcomes framework for diabetes [40].
Figure 2 ADDITION-Leicester algorithm for the diagnosis of pre-diabetes and screen-detected T2DM.
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The routine care arm will be reviewed one and five
years post diagnosis when only anthropometric and bio-
chemical data will be collected. The intensive treatment
team do not engage in the management of these
patients and general practitioners are asked to follow
usual referral procedure if specialist advice or interven-
tion is required.
Intensive care arm intervention
Care for the intensive arm is based upon a paradigm of
multi-factorial intervention shown to improve mortality
in T2DM [41]. Structured education (diabetes education
and self-management for ongoing and newly diagnosed
diabetes - DESMOND [42]) is initially offered to all
patients in the intensive arm with attendance ideally,
within the first two months of diagnosis. Sessions are
delivered by two trained educators and aim to facilitate
lifestyle changes in relation to dietary habits, physical
activity levels, smoking cessation and glucose monitor-
ing. Those participants who are unable, or decline the
opportunity to attend the structured education pro-
gramme are offered one-to-one advice with a dietitian.
All volunteers are offered a glucometer, and encouraged
to maintain a reflective diary. On-going professional
support is provided in the first year through an indivi-
dualised peripatetic clinic offering two monthly visits
from a diabetes specialist nurse or physician. Ultimately,
participants are encouraged to self-manage their dia-
betes by identifying personalised goals which facilitate
individualised behaviour and lifestyle change.
Patients without specific contra-indications are advised
to take aspirin 75 mg orally and prescribed lipid lowering
therapy (simvastatin 40 mg once daily) if total cholesterol
concentration exceeds 3.5 mmoll-1. An individualised,
stepwise approach to management according to specified
algorithms is adopted to ensure optimisation of hyperten-
sion, dyslipidaemia and hyperglycaemia according to pro-
tocol-driven targets using medication within existing
licensed indications (table 2). Recommended drug
choices take in to account treatment efficacy, side-effects
and cost, the main priority being achievement of treat-
ment targets whilst maintaining flexibility and low rates
of adverse events. The approach is deliberately pragmatic
Table 2 ADDITION-Leicester algorithm for the management of hyperglycaemia, hypertension and dyslipidaemia.
Basic Treatment
TARGET
add if above TARGET add if above
TARGET +BMI>19
or creatinine>130
Supplementary treatment
If still above TARGET
Blood
Glucose
HbA1c <6.5%
SMBG Tuition
DESMOND
Dietary Advice
HbA1c >6.5%
SMBG Tuition
DESMOND
Biguanide
HbA1c >6.5%
SMBG Tuition
DESMOND
Insulin
HbA1c >6.5%
Biguanide
Sulphonylureas
Thiazolidinediones
THEN
Stop TZD
Add basal Insulin
(bedtime)
HbA1c >6.5%
and on
Biguanide
Sulphonylureas
Insulin
(basal/bolus)
Intensify & titrate
Insulin
Blood
Pressure
BP
< 130/80 mmHg
No treatment
BP
>130/80 mmHg
ACE
BP
>135/80 mmHg
ARB
CCB
Thiazide
BP
>130/80 mmHg
ACE
ARB/CCB
Thiazide
alpha/beta Blocker
Cholesterol <3.5 mmol/L
Diet
>3.5 mmol/L
TG >6.0 mmol/L
Diet
Statin
Consider
Ezetimibe/Fibrate
Aspirin 75 mg to all patients, unless contraindications of gastrointestinal bleeding, ulcers or haemophilia.
If Aspirin contraindicated, consider Clopidogrel.
KEY
ACE: Perindopril 2-4 mg daily or Ramipril 2.5-10 mg daily
SMBG: self-monitored blood glucose
Biguanide: Metformin 1-2 g daily
Sulphonylurea: Gliclazide MR 30-120 mg daily or Glimepiride 1-4 mg daily
Insulin: Basal analogue: Glargine. Short-acting analogue: Novorapid or Premixed: Novomix30 twice daily
Thiazolidinedione: Pioglitazone 30-45 mg daily
ARB: Angiotensin receptor blocker: Losartan 25-50 mg daily
CCB: Calcium Channel Blocker: Amlodipine 5 mg daily
Thiazide: Bendrofluazide 2.5 mg daily
Alpha/beta blocker: Doxazosin MR 4-8 mg or Bisoprolol 5-10 mg daily
Statin: Simvastatin 20-40 mg or Atorvastatin 20-40 mg daily
Fibrate: Fenofibrate (micro) 267 mg or Bezafibrate MR 400 mg daily
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with the final decision on choice of medication deter-
mined by the health care professional and patient. Treat-
ment targets for the intensive care arm are based on
complex interventions with proven efficacy in T2DM;
HbA1c <7.0% with initiation of treatment at 6.5%, blood
pressure <130/80 mmHg, and total cholesterol <3.5
mmoll-1 [41]. After the first year, community visits are
extended to every four months but continue to be guided
by protocol driven blood pressure, HbA1c%, and lipid
targets.
At annual visits (V1-V4 table 1) interim outcome
measures and additional biomedical assessments are
performed, including urinary albumin creatinine ratio
(ACR), electrocardiography and thyroid function tests.
This visit includes a standardised foot examination
incorporating a vascular doppler assessment, ankle-bra-
chial pressure indices and monofilament neuropathy
testing. A stereoscopic digitalised retinal examination is
performed and independently verified by operators
blinded to the participants study group allocation.
The intensive treatment protocol is externally moder-
ated by the trial steering committee and specifically
designed to achieve HbA1c%, blood pressure and serum
lipid targets below current national recommendations.
Endpoints and outcomes
Primary endpoint
The primary endpoint is reduction in modelled coronary
heart disease at five years using the United Kingdom
Prospective Diabetes Study (UKPDS CHD) risk equation
[43]. The UKPDS CHD risk engine has the advantage of
being diabetes specific and incorporates an adjustment
for the effects of south Asian ethnicity when calculating
CHD risk. It has recently been shown to be as accurate
as other CHD risk assessment tools in T2DM and has
been validated for the effects of ethnicity [43].
Secondary and intermediate outcomes
Secondary outcomes of ADDITION-Leicester are a
microvascular complication composite of diabetic reti-
nopathy, neuropathy or microalbuminuria, a vascular
atherosclerosis surrogate (carotid femoral pulse wave
velocity), all cause mortality (assessed by participants
tagging with the Office for National Statistics), non-fatal
cardiovascular events, hospitalisation, health service cost
and quality of life indicators.
Intermediate outcomes are measured annually in the
intensive care arm and at one, three and five years in
the routine care arm (table 1). These include HbA1c%,
blood pressure, total cholesterol, microalbuminuria, self-
reported hypoglycaemic episodes, weight, physical activ-
ity, ankle-brachial pressure indices and smoking status.
Screening outcomes
Response and attendance characteristics (obtained from
MPLs) will provide an objective assessment of screening
within the invited population. The programme is of suf-
ficient size to enable the feasibility and complexities of
screening to be stratified by ethnicity and socio-eco-
nomic status. Outcomes will include the number of
individuals responding to first and second mailers, pre-
senting for screening, and subsequently diagnosed with
T2DM or IGR. Metabolic dysfunction, cardiovascular
risk, psychological status and self-perceived health in
newly diagnosed T2DM and IGR will be determined.
Population effects of screening will be determined via
Office of National Statistics (ONS) mortality tagging and
self-report health questionnaires five years after screen-
ing. Response and attendance rates will also be com-
pared with previous population T2DM screening studies
to enable specific conclusions to be drawn about the
ADDITION-Leicester population [25,29].
Health economic outcomes
The economic analysis will establish the NHS costs of
Phase 1 (screening) for T2DM and IGR from a patient
and health service perspective. The cost-effectiveness of
multifactorial intervention within our population of
screen-detected cases will be determined from a health
service perspective. Personal patient costs to attend the
assessments (screening and as part of the trial) are col-
lected at each visit. Health service use is assessed using
data on consultations with healthcare professionals, hos-
pitalisations and medications in the twelve months lead-
ing up to annual review.
Statistical methods and power calculation
Assuming a prevalence of screen-detected diabetes of
4.5%, we calculated a target of 7,000 (30% (2,100) South
Asians) volunteers over three years sufficient to identify
a screen-detected T2DM cohort (n = 225) demonstrat-
ing a 6% difference (80% power, alpha 0.05) between
routine and intensive groups at one year assuming an
intra cluster correlation coefficient of 0.14 and allowing
for a loss to follow-up of 15%.
The benefits of screening and intensive treatment will
be assessed using an intention to treat and allowing for
clustering of patients by practice. The UKPDS CHD
score at 5 years will be compared along with all second-
ary outcomes by treatment group, adjusting for differ-
ences in baseline variables. Estimates will be presented
with 95% confidence intervals to reflect uncertainty in
estimations. Sensitivity analysis assuming a range of out-
comes for non-completers will be informed by baseline
data. The primary perspective for the cost analysis will
be the health service, with personal costs as a secondary
perspective. The costs of intensive intervention will be
compared with unit change in health utility at one year.
Costs at one year and future costs derived from existing
data will be compared with modelled risk of death and
cardiovascular events, with appropriate sensitivity
Webb et al. Trials 2010, 11:16
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analysis. The cost of screening and the screening plus
intensive treatment will be compared with changes in
health utility from questionnaire data.
Data entry
Source data, CRF and Questionnaires, are entered by
Abacus Data and Document Capture LTD (Luton, UK)
using double data entry to ensure acceptable accuracy
and validation. Data discrepancies are handled by a
small team of experienced researchers with clinical
input where necessary (levels of agreement >90% discre-
pancies settled by third adjudicating physician).
Funding and timescale
The project is funded for support and treatment costs
by NHS Department of Health Support for Science and
project grants. The screening phase of ADDITION-Lei-
cester is now complete, having invited over 35,000
volunteers and identified 345 new cases of T2DM. As
the intervention is delivered in tandem with the screen-
ing phase, the last trial visit is forecast for May 2012
assuming a mean follow up of 5 years.
Conclusion
Earlier identification of hyperglycaemia through screen-
ing may be an effective way of improving vascular out-
comes in people with T2DM. Although modelling
studies suggest screening is cost-effective [44] the impli-
cations of implementing major screening programmes
are of such magnitude that a sound evidence base is
essential before expert consensus can be reached. We
have described the methodology and design of a large
scale population based screening programme and rando-
mised controlled trial of newly diagnosed T2DM cases.
To our knowledge ADDITION-Leicester is the largest
screening study focusing upon a major ethnic minority
at increased risk of T2DM. The study aims to compre-
hensively describe glucose status (via a glucose tolerance
test) and cardiovascular risk at a population level as well
as describing the practicalities, cost effectiveness and
overall feasibility of cardiovascular risk screening within
this group.
The results will be of major relevance to screening
policy makers and those charged with delivering frame-
works for effective chronic disease management in pri-
mary care. Of particular importance is the emphasis on
south Asians a major yet under researched high risk
ethnic minority group.
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